A randomized double-blind Phase IIb trial to evaluate the efficacy of ChAd63-KH for the treatment of post kala-azar dermal leishmaniasis
Brima M. Younis, Rebecca Wiggins, Eltahir A.G. Khalil, Mohamed Osman, Francesco Santoro, Chiara Sonnati, Ada Keding, Maria Novedrati, Giorgio Montesi, Ali Noureldein, Elmukashfi T. A. Elmukashfi, Ala Eldin Mustafa, Mohammed Alamin, Mohammed Saeed, Khalid Salman, Ahmed J. Suliman, Amin E.A. Musa, Alison M. Layton, Charles J. N. Lacey, View ORCID ProfilePaul M. Kaye, Ahmed M. Musa
doi: https://doi.org/10.1101/2024.04.11.24305597
Brima M. Younis
1Department of Clinical Pathology & Immunology, Institute of Endemic Diseases, University of Khartoum, Sudan
Rebecca Wiggins
2York Biomedical Research Institute, Hull York Medical School, University of York, Heslington, York, UK
Eltahir A.G. Khalil
1Department of Clinical Pathology & Immunology, Institute of Endemic Diseases, University of Khartoum, Sudan
Mohamed Osman
2York Biomedical Research Institute, Hull York Medical School, University of York, Heslington, York, UK
Francesco Santoro
3Department of Medical Biotechnologies, University of Siena, Siena, Italy
Chiara Sonnati
3Department of Medical Biotechnologies, University of Siena, Siena, Italy
Ada Keding
4Department of Health Sciences, University of York, Heslington, York, UK
Maria Novedrati
3Department of Medical Biotechnologies, University of Siena, Siena, Italy
Giorgio Montesi
3Department of Medical Biotechnologies, University of Siena, Siena, Italy
Ali Noureldein
1Department of Clinical Pathology & Immunology, Institute of Endemic Diseases, University of Khartoum, Sudan
Elmukashfi T. A. Elmukashfi
1Department of Clinical Pathology & Immunology, Institute of Endemic Diseases, University of Khartoum, Sudan
Ala Eldin Mustafa
1Department of Clinical Pathology & Immunology, Institute of Endemic Diseases, University of Khartoum, Sudan
Mohammed Alamin
1Department of Clinical Pathology & Immunology, Institute of Endemic Diseases, University of Khartoum, Sudan
Mohammed Saeed
1Department of Clinical Pathology & Immunology, Institute of Endemic Diseases, University of Khartoum, Sudan
Khalid Salman
1Department of Clinical Pathology & Immunology, Institute of Endemic Diseases, University of Khartoum, Sudan
Ahmed J. Suliman
1Department of Clinical Pathology & Immunology, Institute of Endemic Diseases, University of Khartoum, Sudan
Amin E.A. Musa
1Department of Clinical Pathology & Immunology, Institute of Endemic Diseases, University of Khartoum, Sudan
Alison M. Layton
2York Biomedical Research Institute, Hull York Medical School, University of York, Heslington, York, UK
Charles J. N. Lacey
2York Biomedical Research Institute, Hull York Medical School, University of York, Heslington, York, UK
Paul M. Kaye
2York Biomedical Research Institute, Hull York Medical School, University of York, Heslington, York, UK
Ahmed M. Musa
1Department of Clinical Pathology & Immunology, Institute of Endemic Diseases, University of Khartoum, Sudan
Posted April 11, 2024.
A randomized double-blind Phase IIb trial to evaluate the efficacy of ChAd63-KH for the treatment of post kala-azar dermal leishmaniasis
Brima M. Younis, Rebecca Wiggins, Eltahir A.G. Khalil, Mohamed Osman, Francesco Santoro, Chiara Sonnati, Ada Keding, Maria Novedrati, Giorgio Montesi, Ali Noureldein, Elmukashfi T. A. Elmukashfi, Ala Eldin Mustafa, Mohammed Alamin, Mohammed Saeed, Khalid Salman, Ahmed J. Suliman, Amin E.A. Musa, Alison M. Layton, Charles J. N. Lacey, Paul M. Kaye, Ahmed M. Musa
medRxiv 2024.04.11.24305597; doi: https://doi.org/10.1101/2024.04.11.24305597
A randomized double-blind Phase IIb trial to evaluate the efficacy of ChAd63-KH for the treatment of post kala-azar dermal leishmaniasis
Brima M. Younis, Rebecca Wiggins, Eltahir A.G. Khalil, Mohamed Osman, Francesco Santoro, Chiara Sonnati, Ada Keding, Maria Novedrati, Giorgio Montesi, Ali Noureldein, Elmukashfi T. A. Elmukashfi, Ala Eldin Mustafa, Mohammed Alamin, Mohammed Saeed, Khalid Salman, Ahmed J. Suliman, Amin E.A. Musa, Alison M. Layton, Charles J. N. Lacey, Paul M. Kaye, Ahmed M. Musa
medRxiv 2024.04.11.24305597; doi: https://doi.org/10.1101/2024.04.11.24305597
Subject Area
Subject Areas
- Addiction Medicine (343)
- Allergy and Immunology (666)
- Anesthesia (180)
- Cardiovascular Medicine (2630)
- Dermatology (222)
- Emergency Medicine (397)
- Epidemiology (12183)
- Forensic Medicine (10)
- Gastroenterology (756)
- Genetic and Genomic Medicine (4071)
- Geriatric Medicine (387)
- Health Economics (679)
- Health Informatics (2628)
- Health Policy (998)
- Hematology (362)
- HIV/AIDS (845)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (431)
- Neurology (3840)
- Nursing (209)
- Nutrition (571)
- Oncology (2011)
- Ophthalmology (582)
- Orthopedics (239)
- Otolaryngology (304)
- Pain Medicine (250)
- Palliative Medicine (74)
- Pathology (471)
- Pediatrics (1109)
- Primary Care Research (449)
- Public and Global Health (6504)
- Radiology and Imaging (1390)
- Respiratory Medicine (869)
- Rheumatology (401)
- Sports Medicine (341)
- Surgery (441)
- Toxicology (52)
- Transplantation (185)
- Urology (165)